SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement

SARS-CoV-2 has caused a global health crisis and mass vaccination programmes provide the best opportunity for controlling transmission and protecting populations. Despite the impressive clinical trial results of the BNT162b2 (Pfizer/BioNTech), ChAdOx1 nCoV-19 (Oxford/AstraZeneca), and mRNA-1273 (Mod...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Lancet Gastroenterol Hepatol
Päätekijät: Alexander, James L, Moran, Gordon W, Gaya, Daniel R, Raine, Tim, Hart, Ailsa, Kennedy, Nicholas A, Lindsay, James O, MacDonald, Jonathan, Segal, Jonathan P, Sebastian, Shaji, Selinger, Christian P, Parkes, Miles, Smith, Philip J, Dhar, Anjan, Subramanian, Sreedhar, Arasaradnam, Ramesh, Lamb, Christopher A, Ahmad, Tariq, Lees, Charlie W, Dobson, Liz, Wakeman, Ruth, Iqbal, Tariq H, Arnott, Ian, Powell, Nick
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier Ltd. 2021
Aiheet:
Rapid Review
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7834976/
https://ncbi.nlm.nih.gov/pubmed/33508241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2468-1253(21)00024-8
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia